Merck KGaA is thinking big...bigger...and even bigger. The company's new chairman, Karl Ludwig Kley (photo), says he's planning a series of acquisitions over the next three years to grow its consumer health and life sciences businesses, all while expanding its pharma and liquid crystal divisions from within. The aim: $13.9 billion in sales by 2010.
That's no chump change, and it'll take several billions' worth of acquisitions to get there. But challenging or no, it's a focused strategy, which is more than Merck KGaA has had over the past couple of years, given the exit of Kley's predecessor, the sell-off of the company's generics division, and its buyoutÂ of the Swiss biotech Serono.
- read this articleÂ in the Financial Times
Mylan inks $6.6B deal for Merck's generic drug biz. Report
Merck KGaA buying control of Serono. Report
Bayer outbids Merck KGaA for Schering. Report
Gene Logic takes fresh look at Merck KGaA drugs. Report
The Top 5 Buyouts of 2007. Report